Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 233   

Articles published

PFE 33.54 -0.08 (-0.24%)
price chart
Pfizer Downgraded on Patent Expiration for Viagra: Credit Suisse
U.S. pharmaceutical giant Pfizer Inc. (PFE) is in trouble as it faces two “meaningful” patent expirations for its male impotency treatment drug Viagra and nerve damage treatment drug Lyrica, according to analysts at Credit Suisse.
Pfizer Inc. (PFE) Closes 0.24% Down on the Day for July 20  Equities.com
Analyst Prescribes Neutral Rating For Pfizer Shares  Benzinga
Pfizer nabs European rights to antifungal isavuconazole
Pfizer (NYSE:PFE) inks an agreement with Swiss drugmaker Basilea Pharmaceutica Ltd. securing exclusive commercial rights in Europe to CRESEMBA (isavuconazole), an antifungal drug for the treatment of adults with invasive aspergillosis and ...
Pfizer Completes License Agreement For The Exclusive Commercialization ...  Business Wire (press release)
Pfizer Inc. (PFE) Has Obtained Exclusive Commercialization Rights In Europe ...  Investing News Update
Pfizer cuts losses on Brazil drug maker with sale for nominal sum
Pharma giant Pfizer Inc (NYSE:PFE) has bitten the bullet on its Brazil generic drug making business after failing to find a buyer for its 40% stake.
Lightning Round: Jim Cramer Shares His Thoughts On GameStop, Pfizer And More
On CNBC's "Mad Money Lightning Round", Jim Cramer said he doesn't want to buy GameStop Corp. (NYSE: GME). He would rather own Activision Blizzard, Inc. (NASDAQ: ATVI), Electronic Arts Inc. (NASDAQ: EA) and Take Two Interactive Software Inc ...
Is It Time to go for Pfizer Inc. (PFE), Automatic Data Processing, Inc. (ADP)?
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.
Pfizer: Is It Really That Bad?
And indeed this can cause problems for Pfizer, but this company is more than capable of offsetting these difficulties.
Better Buy: Pfizer Inc. vs. Eli Lilly and Company
Pfizer (NYSE:PFE) might be more than twice as big as fellow drugmaker Eli Lilly and Company (NYSE:LLY), but Lilly has been the better investment choice for quite a while.
Pfizer Announces NDA Filing Acceptance By FDA For XELJANZ
Today, Pfizer (PFE) announced that its supplemental new drug application -- sNDA -- has been accepted for review by the FDA.
Pfizer: FDA Accepts SNDA For Xeljanz For Treatment Of Ulcerative Colitis  Nasdaq
(tofacitinib citrate) for the Treatment of Adult Patients with Moderately to ...  Business Wire (press release)
Pfizer receives token payment to exit Brazil venture, sources say
SAO PAULO (Reuters) - Pfizer Inc (PFE.N) has agreed to exit Laborat�rio Teuto Brasileiro SA for a token amount after failing to find a buyer for the 40 percent stake it held in the Brazilian generic drugmaking joint venture, two people with knowledge ...
Kempner Capital Management Inc. Buys Williams-Sonoma Inc, Pfizer Inc, The ...
Kempner Capital Management Inc. initiated holdings in Pfizer Inc. The purchase prices were between $31.75 and $34.34, with an estimated average price of $33.25.